How does succinate dehydrogenase inhibition drive multicellular cardiac repair?

Cell-specific Sdhb deletion shows fibroblasts, not cardiomyocytes, drive the functional benefit of transient SDH inhibition after MI.

Direct answer

Transient inhibition of succinate dehydrogenase (SDH) with malonate improves cardiac repair after myocardial infarction by acting on at least two cell types, but the two contributions are not equivalent. Deleting Sdhb in cardiomyocytes only produced a transient burst of cardiomyocyte proliferation and did not improve post-infarction function, whereas deleting Sdhb in myofibroblasts suppressed their activation and fibrosis and improved cardiac function. The paper therefore reframes SDH inhibition as a multicellular metabolic–epigenetic intervention, with the antifibrotic fibroblast arm carrying the functional benefit in these genetic models.

1sources cited

This article was generated with WisPaper-powered search and paper analysis.

Why one cell type cannot explain the benefit

The starting puzzle is a mismatch between pharmacology and genetics. Malonate, a competitive SDH inhibitor, had already been reported by the same group to promote regeneration after myocardial infarction (MI) in adult mice. SDH is the mitochondrial complex that converts succinate to fumarate in the tricarboxylic acid (TCA) cycle. If the regenerative effect simply reflected more cardiomyocyte division, then permanently removing Sdhb from cardiomyocytes should reproduce it. The paper tests that assumption directly and finds it does not hold.

The authors used two genetic models in which Sdhb is deleted in a chosen cell type, alongside the pharmacological malonate model. They then combined single-nucleus RNA sequencing and single-nucleus ATAC-seq, which measure gene expression and chromatin accessibility in individual nuclei, with CUT&RUN profiling of histone marks. This design lets them ask both which cells change and what chromatin state accompanies the change, rather than inferring mechanism from whole-heart tissue.

The key comparison is between cell-specific deletions. Cardiomyocyte-specific Sdhb deletion increased proliferation markers at early time points but left cardiac function unchanged after MI. Myofibroblast-specific Sdhb deletion reduced fibrosis and improved function without inducing cardiomyocyte proliferation. Neither single deletion phenocopies transient malonate treatment, which the authors interpret as evidence that the drug's benefit requires coordinated effects across cell types and a reversible mode of inhibition.

Cardiomyocyte Sdhb loss gives proliferation without recovery

In cardiomyocyte-specific Sdhb knockout (Sdhbcko) hearts, Ki67, pH3 and Aurora B staining marked cycling cardiomyocytes. The increases were transient: at 2 weeks after tamoxifen induction, Ki67+ cardiomyocytes were higher in Sdhbcko than control hearts (P = 0.0015), and pH3+ and Aurora B+ cardiomyocytes were also elevated (P = 0.0003 and P = 0.0010). By 4 weeks, none of these markers differed significantly between groups.

That transient proliferation did not translate into functional recovery. The paper reports that cardiomyocyte-specific deletion reduced scar area but failed to restore cardiac function after MI. The authors connect this to the reversibility of malonate: transient inhibition allows cardiomyocytes to re-enter the cell cycle and later resume oxidative metabolism and maturation, whereas permanent Sdhb deletion removes the recovery phase. They also note that sustained SDH loss may constrain pyrimidine biosynthesis and induce replication stress, so elevated aspartate in knockout hearts may not be enough to sustain proliferation.

This is the paper's clearest caution against reading proliferation markers as regeneration. A rise in cycling cardiomyocytes is a measured cellular event, not proof of restored pump function, and the two outcomes diverge in the same genetic model.

Myofibroblast Sdhb loss suppresses fibrosis and improves function

The fibroblast arm behaves differently. In myofibroblast-specific Sdhb knockout (Sdhbfko) mice, the fraction of SDHB+ PDGFRα+ cardiac fibroblasts fell at 1 week after MI (P = 0.0001, n = 6 mice per group), confirming effective deletion in the targeted population. At 4 weeks, Sdhbfko hearts showed a lower heart weight-to-body weight ratio (P = 0.0061) and reduced fibrotic area (P = 0.0019) and fibrotic area percentage (P = 0.0055) than controls.

Echocardiography tracked the functional consequence over time. Ejection fraction and fractional shortening did not differ before MI or at 1 week, but were significantly higher in Sdhbfko mice at 2 and 4 weeks (ejection fraction P = 0.0328 and P = 0.0311; fractional shortening P = 0.0245 and P = 0.0246). Surviving myocardial area at 1 week did not differ between groups (P = 0.3395), which argues against the functional gain being explained by greater early cardiomyocyte survival.

The authors interpret this as fibroblasts being a major cellular target of SDH inhibition. In their model, suppressing myofibroblast activation reduces scar deposition, and that antifibrotic effect is sufficient to improve function even without a cardiomyocyte proliferation signal.

Transient inhibition differs from permanent deletion

The paper's central mechanistic argument rests on a contrast between two ways of lowering SDH activity. Malonate produces transient, reversible inhibition and acts across multiple cell types. Genetic Sdhb deletion permanently disables the complex in one cell type. The authors argue that this difference explains why the drug restores function while single-cell deletions do not.

Their biphasic model holds that transient suppression of oxidative metabolism allows cardiomyocytes to re-enter the cell cycle, and that later restoration of oxidative metabolism supports redifferentiation and completion of regeneration. The malonate-responsive cardiomyocyte subcluster sits between glycolytic and fatty acid oxidative programs, which the authors read as a transitional state consistent with that sequence. Permanent deletion would preclude the restoration step.

This interpretation is the authors' model rather than a directly measured flux experiment. The metabolomic profiling measured steady-state metabolite pools without isotope tracing, so the paper cannot show how TCA intermediates are routed during regeneration. The authors acknowledge that flux-based approaches are needed, and they also note that succinate and malate promoted proliferation in hiPSC-derived cardiomyocytes even though both were reduced in Sdhbcko hearts, suggesting increased turnover rather than simple availability.

The fibroblast arm carries the functional benefit

For readers weighing what matters most in this paper, the decisive comparison is between the two cell-specific models. Cardiomyocyte Sdhb deletion produced the more visually striking phenotype, a transient wave of cardiomyocyte proliferation, yet did not improve post-MI function. Myofibroblast Sdhb deletion produced no cardiomyocyte proliferation signal but did reduce fibrosis and improve ejection fraction and fractional shortening by 2 to 4 weeks. In this system, the antifibrotic arm is the one tied to functional recovery.

That priority comes with explicit scope conditions. The single-nucleus and CUT&RUN analyses were performed at one time point, 14 days after MI, so earlier initiating events may be missed. The cell-specific knockouts cover cardiomyocytes and myofibroblasts but not other cardiac cell types, and the authors note that myeloid populations showed distinct transcriptional signatures between treatment groups. Long-term safety of transient SDH inhibition, including cardiomyocyte maturation, electrical integration and arrhythmogenic risk, remains unknown.

The practical reading is not that cardiomyocyte proliferation is irrelevant, but that in this paper it is insufficient on its own. A candidate SDH-inhibiting strategy should be judged on whether it engages the fibroblast arm and preserves the reversibility that allows cardiomyocytes to mature afterward, rather than on proliferation markers alone.

Sources used in this answer

1

A metabolic–epigenetic switch governs multicellular cardiac repair following succinate dehydrogenase inhibition

Cell-specific Sdhb deletion shows that myofibroblast SDH loss suppresses fibrosis and improves post-MI function, whereas cardiomyocyte SDH loss only transiently increases proliferation without functional recovery.